Chinese infant formula maker Synutra has blamed a competitive promotional environment and unfavourable foreign exchange rates for a fall in nine month sales and profits.
The firm has now lowered its full year outlook to $375-$400m for net sales from $450-$500m and net income of $30-35m from $50-60m.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Net profit for the nine months ending 31 December fell to US$20.9m from $47.8m a year earlier. Operating profit was also lower at $46m compared with $57.2m
Sales declined to $278.9m from $303.7m.
Sales were impacted by a fall in Synutra’s nutritional foods arm where a decline was seen in the sales volume and average selling price in milk formula as well as a sales decline in the firm’s industrial arm.
For the third quarter sales were lower at $109.3m compared with $115.3m.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataOperating income however was lifted by the lower cost of whole milk powder and grew to $20.6m from $19.2m.
But net profit fell on higher foreign exchange losses and income tax expenses to $12.3m from $17.9m.
In January, the firm’s CEO Liang Zhang expressed wishes to take the company private by acquiring all outstanding stock for US$5.91 a share. In an update from Friday (5 February), Synutra said it had appointed an independent financial advisor and legal counsel in connection with the proposal.
